Table 2.
Characteristics before and after propensity-score matching in groups M and A
| Before propensity-score matching | ||||
|---|---|---|---|---|
| group M (%) | group A (%) | P value | Standardized difference | |
| Number of patients (N) | 181 | 195 | ||
| Age (years) | 64.2 ± 14.3 | 62.8 ± 15.7 | 0.38 | 0.09 |
| Sex, male | 53 (29.3%) | 85 (43.6%) | < 0.01 | 0.30 |
| ASA-PS classification, I | 170 (93.9%) | 192 (98.5%) | 0.03 | 0.24 |
| Malignant diseases | 54 (29.8%) | 83 (42.6%) | 0.01 | 0.27 |
| Procedure time (min) | 15.8 ± 7.7 | 20.0 ± 11.6 | < 0.01 | 0.43 |
| Mean midazolam dose (mg) | 4.7 ± 1.6 | 4.0 ± 1.5 | < 0.01 | 0.45 |
| Using analgesic agent | 57 (31.5%) | 37 (19.0%) | 0.01 | 0.29 |
| After propensity-score matching | ||||
| group M (%) | group A (%) | P value | Standardized difference | |
| Number of patients (N) | 120 | 120 | ||
| Age (years) | 63.4 ± 15.2 | 62.7 ± 15.6 | 0.76 | 0.05 |
| Sex, male | 42 (35.0%) | 35 (29.2%) | 0.41 | 0.12 |
| ASA-PS classification, I | 117 (97.5%) | 117 (97.5%) | 1.00 | 0.00 |
| Malignant diseases | 43 (35.8%) | 39 (32.5%) | 0.68 | 0.07 |
| Procedure time (min) | 17.0 ± 8.0 | 16.8 ± 8.6 | 0.81 | 0.02 |
| Mean midazolam dose (mg) | 4.4 ± 1.6 | 4.3 ± 1.7 | 0.67 | 0.06 |
| Using analgesic agent | 29 (24.2%) | 23 (19.2%) | 0.43 | 0.12 |
Results are presented as the number of patients or mean ± standard deviation. ASA-PS: American Society of Anesthesiologists physical status, group M: discharge standard using the modified post-anesthetic discharge scoring system, group A: discharge standard using the modified Aldrete score